BIO
The COVID-19 pandemic greatly impacted how pharmaceutical companies approach vaccine development. One key aspect was the sharp increase in partnerships between pharmaceutical companies and contract development and manufacturing organisations (CDMOs) in order to speed up their vaccine development.
During this time, many CDMOs expanded their integrated service offerings for messenger ribonucleic acid (mRNA) vaccines and other cutting-edge technologies to offer comprehensive support across the vaccine development journey.
Many CDMOs also invested in their aseptic processing and sterile fill and finish capacity to support their partners’ high-volume vaccine manufacturing efforts.
The pandemic also highlighted pandemic frictions across the administration process for parenteral vaccines, limiting the number of people we could vaccinate per day.
Looking ahead to a post-COVID world, the industry can explore how to remove this friction in future mass vaccination campaigns by using alternative delivery methods such as oral or inhalation.
Additionally, these treatments also offer the advantages of rapid and potentially pain-free administration and are being actively explored for vaccine delivery.
In a recent discussion with Pharm Tech, Recipharm, and Kai Lipinski, Vibalogics (a Recipharm company) explore the future of vaccine development and how CDMOs can help their partners bring effective and patient-centric vaccines to market in the future.